Most firms enter a mass tort late, after the docket already shows scale. By then the claimants cost more, the media is sold, and the return has compressed. The market moves months before the filings do.
Case acquisition is the whole game. A lead is not a case, and a case is not a payout. This guide covers what a signed case actually costs, whether to buy leads or generate them, how to vet a lead vendor, and which torts are live right now. Then it hands you a read on all 12.
What is mass tort marketing and case acquisition?
Mass tort marketing is the paid work of finding people harmed by the same product or drug, qualifying them, and signing them as clients. It spans broadcast, connected TV, paid search, and paid social, aimed at one injury category at a time.
It is not personal injury marketing. A car crash produces a local claimant this week. A mass tort produces a national pool over years, gated by medical records, filing deadlines, and a federal docket. The buyer is a firm or a litigation funder deciding whether a case pool is worth the capital. Mass tort TV spend hit $220 million in 2022, and a third of the top spenders were lead generators, not law firms.
How much does it cost to acquire a mass tort case?
It runs from about $68 to $15,000 per signed case. The spread is more than 200x, and it tracks two things: how many claimants exist, and how much each case is worth. A crowded tort with a huge pool costs little per lead. A rare, high-value injury costs a fortune per signed file.
| Tort | Signed-case acquisition cost |
|---|---|
| Ozempic / GLP-1 | $68 to $347 |
| Social media addiction | $386 to $772 |
| Talcum powder | $470 to $940 |
| Roundup | $2,500 to $3,500 |
| Camp Lejeune | $3,500 to $5,000 |
| Mesothelioma | $5,000 to $15,000 |
Read the cost against the case, not on its own. A $15,000 mesothelioma acquisition sits against a case worth $1M or more. A $772 social media addiction lead can still lose money into a broken intake. Cost per case only means something next to case value and your conversion rate.
Should you buy mass tort leads or generate your own?
Bought leads are fast and usually shared. A vendor sells the same claimant to several firms, so you race competitors to the phone and your conversion drops. Generated leads are slower and exclusive, and they sign at a higher rate because the claimant chose you.
Buy Leads
- Fast to turn on, no build time
- Often shared across firms
- You compete to sign the same claimant
- Vendor owns the acquisition method
- Cost per signed case climbs as sharing rises
Generate Your Own
- Slower to stand up, needs media and creative
- Exclusive to your firm
- Higher sign rate, the claimant picked you
- You own the data and the audience
- Compounds as the tort matures
Neither path skips intake. A vendor hands you a contact, not a signed case. The same conversion math that governs personal injury leads governs these, so read the full cost breakdown in our buying versus generating leads chapter before you commit a budget.
Which mass torts are active right now?
Every tort sits somewhere on a lifecycle: emerging, growth, peak, or declining. The stage decides your entry math. Emerging torts are cheap to enter and slow to pay. Peak torts are proven and expensive. Declining torts can be dead money if the filing window has closed.
Read the stage before the retainer. The directory below reads all 12 active torts by stage, pool size, and litigation status, so you enter on the math, not the pitch.
Why rideshare assault is the tort to watch
Rideshare assault is the fastest-growing tort in the top tier. It runs across two federal dockets, 6,000-plus cases against Uber and Lyft combined, and the first federal bellwether returned an $8.5M verdict in February 2026. Discovery surfaced 400,000-plus misconduct reports the platform had not disclosed.
Here is the acquisition edge. This tort is digital-first. TV spend on it is effectively zero, and Meta inventory is already worked hard. The claimant pool is huge and under-served, which means the firms reading it now enter before the media war starts, not after.
How do you vet a mass tort lead vendor?
Most acquisition losses start with a bad vendor, not a bad tort. Shared leads, thin qualification, and no chain of consent turn a cheap lead into an expensive nothing. Run every vendor through the same checklist before a dollar moves.
Exclusive or shared
Qualification depth
Consent and provenance
Return and replacement
Trace to signed cases
The 12 active mass torts: read before you bid
These are the 12 torts we track firm by firm. Each page reads the lifecycle stage, lead economics, channel spend, and litigation status, so you enter the market the way its buyers do. Start at the mass tort intelligence index or read each tort direct.
Emerging (cheap entry, slow payout)
- PFAS / Forever Chemicals: the largest emerging tort, with $120B to $165B in projected liability and 15,220-plus personal injury cases, but zero PI settlements paid yet. The earliest entry point in the biggest liability event in mass tort history.
Growth (rising volume, widening windows)
- Depo-Provera: the number-two hot tort, 3,335-plus MDL cases growing 300 a month, after the FDA added a meningioma warning in December 2025.
- Rideshare assault: the number-three hot tort, 6,000-plus cases across two MDLs, an $8.5M first federal verdict, and near-zero TV spend.
- Hair relaxer: 11,440-plus cases growing 17% a year, the most demographic-specific tort on record, with an April 2026 Daubert deadline as the inflection point.
- Ozempic / GLP-1: two active MDLs, 3,400-plus cases, and the cheapest acquisition in the market at $68 to $347, against a 15M to 33M patient pool.
- NEC: the highest value, lowest volume tort, roughly 1,000 cases and $555M in state court verdicts, with the first Enfamil bellwether set for July 2026.
Peak (proven, expensive, competitive)
- Social media addiction: the number-one ranked hot tort, 2,407-plus MDL cases, with TikTok and Snap already settled and Meta in an active bellwether trial.
- Talcum powder: the largest active MDL in the country, 69,000-plus cases, a $1.56B Baltimore verdict, and J&J’s third bankruptcy attempt failed in 2025.
- Mesothelioma: the permanent tort, $100M-plus in annual ad spend, over $30B left in asbestos trust funds, and cases still forming into the 2040s.
- Paraquat: 6,500-plus MDL cases with a settlement framework signed and the maker ceasing production, a closing acquisition window with CPAs down to $711.
Declining (windows closing or closed)
- Roundup: $16B-plus already paid by Bayer and a $7.25B class settlement pending, with a Supreme Court preemption case as the wildcard.
- Camp Lejeune: the tort that broke the lead market, a $250M ad blitz and 410,000 claims, now with a closed filing deadline and a dead lead market.
Where mass tort marketing sits in the funnel
Acquisition fills the top. Intake and attribution decide what survives. A firm that reads the tort right, buys clean leads, and traces every signed case gets more retainers from the same spend, then scales the torts the data proves.
Run mass tort as five vendors with five reports and the seams cost you cases. Run it off one market read, with one measurement spine, and it compounds. That is the case for a single media desk over a stack of point tools. Pair this guide with law firm lead generation for the acquisition stack and connected TV for the awareness that makes the search cheaper.
How much does it cost to acquire a mass tort case?
Signed-case acquisition runs from about $68 to $15,000, depending on the tort. Cheap, high-volume torts like Ozempic sign at $68 to $347. Rare, high-value torts like mesothelioma run $5,000 to $15,000. Read the cost against the case value and your conversion rate, never on its own.
Should a law firm buy mass tort leads or generate its own?
Bought leads turn on fast but are usually shared across firms, so you compete to sign the same claimant and your conversion drops. Generated leads are exclusive and sign higher because the claimant chose you, but they take media, creative, and time to stand up. Most firms with scale run both and trace each source to signed cases.
Which mass torts are most active right now?
Social media addiction, Depo-Provera, and rideshare assault rank as the top three hot torts. Talcum powder holds the largest active MDL at 69,000-plus cases, and PFAS is the largest emerging tort by projected liability. Each sits at a different lifecycle stage, which changes the entry math. Read all 12 in the directory above.
How do you vet a mass tort lead vendor?
Confirm whether leads are exclusive or shared, check how deeply the vendor qualifies each claimant, get the source and TCPA consent for every lead, and set return terms for dead or duplicate leads up front. Then trace each vendor to signed retainers, not raw lead counts. Cost per lead misleads. Cost per signed case tells the truth.
Why is timing so important in mass tort marketing?
Ad spend on an emerging tort leads the federal filing wave by roughly 90 days, so the money moves before the docket shows scale. Enter early and claimants cost less and media is available. Enter late and you pay peak prices for a crowded pool. Reading the lifecycle stage before you bid is the whole edge.